Doxycycline for the treatment of nodding syndrome (DONS); the study protocol of a phase II randomised controlled trial.
Doxycycline
Nodding syndrome
Onchocerca volvulus
Randomized controlled trial
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
06 Mar 2019
06 Mar 2019
Historique:
received:
25
04
2018
accepted:
13
02
2019
entrez:
8
3
2019
pubmed:
8
3
2019
medline:
16
4
2019
Statut:
epublish
Résumé
Nodding syndrome is a poorly understood neurological disorder of unknown aetiology, affecting several thousand children in Africa. There has been a consistent epidemiological association with infection by the filarial parasite, Onchocerca volvulus and antibodies to leiomodin and DJ-1, cross-reacting with O.volvulus proteins, have been reported. We hypothesized that nodding syndrome is a neuro-inflammatory disorder, induced by antibodies to O.volvulus or its symbiont, Wolbachia, cross-reacting with human neuron proteins and that doxycycline, which kills Onchocerca through effects on Wolbachia, may be used as treatment. This will be a two-arm, double-blind, placebo-controlled, randomised phase II trial of doxycycline 100 mg daily for six weeks in 230 participants. Participants will be patients' ages≥8 years with nodding syndrome. They will receive standard of care supportive treatment. All will be hospitalised for 1-2 weeks during which time baseline measurements including clinical assessments, EEG, cognitive and laboratory testing will be performed and antiepileptic drug doses rationalised. Participants will then be randomised to either oral doxycycline (Azudox®, Kampala Pharmaceutical Industries) 100 mg daily or placebo. Treatment will be initiated in hospital and continued at home. Participants will be visited at home at 2, 4 and 6 weeks for adherence monitoring. Study outcomes will be assessed at 6, 12, 18 and 24-month visits. Analysis will be by intention to treat. The primary efficacy outcome measure will be the proportion of patients testing positive and the levels or titires of antibodies to host neuron proteins (HNPs) and/or leiomodin at 24 months. Secondary outcome measures will include effect of the intervention on seizure control, inflammatory markers, cognitive function, disease severity and quality of life. This trial postulates that targeting O.volvulus through drugs which kill Wolbachia can modify the pathogenic processes in nodding syndrome and improve outcomes. Findings from this study are expected to substantially improve the understanding and treatment of nodding syndrome. Registered with clinicaltrials.gov ID: NCT02850913 on 1st August, 2016.
Sections du résumé
BACKGROUND
BACKGROUND
Nodding syndrome is a poorly understood neurological disorder of unknown aetiology, affecting several thousand children in Africa. There has been a consistent epidemiological association with infection by the filarial parasite, Onchocerca volvulus and antibodies to leiomodin and DJ-1, cross-reacting with O.volvulus proteins, have been reported. We hypothesized that nodding syndrome is a neuro-inflammatory disorder, induced by antibodies to O.volvulus or its symbiont, Wolbachia, cross-reacting with human neuron proteins and that doxycycline, which kills Onchocerca through effects on Wolbachia, may be used as treatment.
METHODS
METHODS
This will be a two-arm, double-blind, placebo-controlled, randomised phase II trial of doxycycline 100 mg daily for six weeks in 230 participants. Participants will be patients' ages≥8 years with nodding syndrome. They will receive standard of care supportive treatment. All will be hospitalised for 1-2 weeks during which time baseline measurements including clinical assessments, EEG, cognitive and laboratory testing will be performed and antiepileptic drug doses rationalised. Participants will then be randomised to either oral doxycycline (Azudox®, Kampala Pharmaceutical Industries) 100 mg daily or placebo. Treatment will be initiated in hospital and continued at home. Participants will be visited at home at 2, 4 and 6 weeks for adherence monitoring. Study outcomes will be assessed at 6, 12, 18 and 24-month visits. Analysis will be by intention to treat. The primary efficacy outcome measure will be the proportion of patients testing positive and the levels or titires of antibodies to host neuron proteins (HNPs) and/or leiomodin at 24 months. Secondary outcome measures will include effect of the intervention on seizure control, inflammatory markers, cognitive function, disease severity and quality of life.
DISCUSSION
CONCLUSIONS
This trial postulates that targeting O.volvulus through drugs which kill Wolbachia can modify the pathogenic processes in nodding syndrome and improve outcomes. Findings from this study are expected to substantially improve the understanding and treatment of nodding syndrome.
TRIAL REGISTRATION
BACKGROUND
Registered with clinicaltrials.gov ID: NCT02850913 on 1st August, 2016.
Identifiants
pubmed: 30841858
doi: 10.1186/s12883-019-1256-z
pii: 10.1186/s12883-019-1256-z
pmc: PMC6402111
doi:
Substances chimiques
Antiparasitic Agents
0
Doxycycline
N12000U13O
Banques de données
ClinicalTrials.gov
['NCT02850913']
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
35Subventions
Organisme : Medical Research Council
ID : MC_UU_00027/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M025489/1
Pays : United Kingdom
Références
Epilepsy Res. 1998 May;30(3):247-51
pubmed: 9657652
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
Afr Health Sci. 2013 Jun;13(2):183-204
pubmed: 24235915
Trans R Soc Trop Med Hyg. 1961 Mar;55:188-91
pubmed: 13767192
Glob Health Action. 2018;11(1):1431362
pubmed: 29382251
BMJ. 2012 Jan 13;344:e349
pubmed: 22246270
Sci Transl Med. 2017 Feb 15;9(377):
pubmed: 28202777
Afr Health Sci. 2013 Jun;13(2):219-32
pubmed: 24235917
Lancet Neurol. 2003 Dec;2(12):714
pubmed: 14649236
Epilepsia. 2008 Dec;49(12):2008-15
pubmed: 18503562
Int J Infect Dis. 2013 Mar;17(3):e149-52
pubmed: 23137614
Epilepsy Res. 2006 Oct;71(2-3):135-41
pubmed: 16870397
Int J Infect Dis. 2016 Apr;45:112-7
pubmed: 26987477
Brain Dev. 1997 Nov;19(7):447-51
pubmed: 9408589
Clin Infect Dis. 2015 Aug 15;61(4):517-26
pubmed: 25948064
MMWR Morb Mortal Wkly Rep. 2012 Jan 27;61(3):52-4
pubmed: 22278159
Lancet Neurol. 2011 Aug;10(8):759-72
pubmed: 21777830
Clin Infect Dis. 2007 Jan 1;44(1):53-60
pubmed: 17143815
Trop Doct. 2010 Jul;40(3):173-5
pubmed: 20555049
PLoS One. 2013 Jun 18;8(6):e66419
pubmed: 23823012
Res Dev Disabil. 2012 Jul-Aug;33(4):1068-75
pubmed: 22502831
BMJ Open. 2013 May 03;3(5):
pubmed: 23645924
Am J Trop Med Hyg. 1996 Jan;54(1):80-3
pubmed: 8651377
Fortschr Neurol Psychiatr Grenzgeb. 1964 May;32:213-59
pubmed: 14147859
Afr Health Sci. 2012 Sep;12(3):242-8
pubmed: 23382736
Lancet Neurol. 2013 Feb;12(2):166-74
pubmed: 23305742
Epilepsia. 2011 Oct;52 Suppl 8:8-11
pubmed: 21967350